Ultra-low-pass whole genome sequencing (ULP-WGS) of circulating tumor DNA appears to provide important prognostic information regarding patients with large B-cell lymphoma (LBCL), according to ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Whole-genome sequencing (WGS) of tumor and germline can generate actionable molecular insights that can guide precision medicine efforts in salivary gland cancer (SGC), according to a new study in JCO ...

Rare disorders arise from genetic alterations that interfere with essential cellular functions. Although each condition ...

Medicare Part B data show that of the 20 CPT codes seeing the largest increase in payments from 2022 to 2024, all are for molecular- or sequencing-based tests.

Genomes are key to unlocking life's evolutionary history. The presence and absence of certain genetic sequences and mutations ...

The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

A new genomic method has enabled multiple people with rare conditions to receive diagnoses that were previously unattainable ...

The acquisition, which enables Qiagen to enter the single-cell sequencing market, is expected to close in December and contribute $40 million to 2026 revenues.